Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

There is considerable evidence that the epidermal growth factor receptor (EGFR) and IGF-I receptor (IGF-IR) cross-talk in breast cancer cells. In the present study, we have examined whether EGFR/IGF-IR cross-talk exists in EGFR-positive tamoxifen-resistant variants of MCF-7 (Tam-R) and T47D (T47D-R) breast cancer cell lines. Although Tam-R cells expressed reduced IGF-IR protein levels compared with their wild-type MCF-7 counterparts, phosphorylated IGF-IR protein levels were equivalent in the two cell lines under basal growth conditions, possibly as a consequence of increased IGF-II expression in Tam-R cells. IGF-II activated both IGF-IR and EGFR in Tam-R cells, whereas only activation of IGF-IR was observed in wild-type cells. In contrast, epidermal growth factor rapidly induced EGFR, but not IGF-IR, phosphorylation in Tam-R cells. IGF-II promoted direct association of c-SRC with IGF-IR, phosphorylated c-SRC, and increased EGFR phosphorylation at tyrosine 845, a c-SRC-dependent phosphorylation site. Pretreatment with either AG1024 (IGF-IR-specific inhibitor) or an IGF-II neutralizing antibody inhibited basal IGF-IR, c-SRC, and EGFR phosphorylation, and AG1024 significantly reduced Tam-R basal cell growth. The c-SRC inhibitor SU6656 also inhibited growth, reduced basal and IGF-II-induced c-SRC and EGFR phosphorylation, and blocked EGFR activation by TGFalpha. Similarly, in T47D-R cells, AG1024 and SU6656 inhibited basal and IGF-II-induced phosphorylation of c-SRC and EGFR, and SU6656 reduced TGFalpha-induced EGFR activity. These results suggest the existence of a unidirectional IGF-IR/EGFR cross-talk mechanism whereby IGF-II, acting through the IGF-IR, regulates basal and ligand-activated EGFR signaling and cell proliferation in a c-SRC-dependent manner in Tam-R cells. This cross-talk between IGF-IR and EGFR is not unique to Tam-R cells because this mechanism is also active in a tamoxifen-resistant T47D-R cell line.

[1]  H. W. van den Berg,et al.  The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. , 1999, Cancer letters.

[2]  I. Ellis,et al.  Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. , 1993, European journal of cancer.

[3]  S. Korsmeyer,et al.  Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[4]  J. Cairns,et al.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.

[5]  Type 1 insulin-like growth factor receptor expression and activation in clinical breast cancer [Abstract] , 2003 .

[6]  J. Zalcberg,et al.  Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line , 1999, British Journal of Cancer.

[7]  D. Coppola,et al.  A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor , 1994, Molecular and cellular biology.

[8]  I. Ellis,et al.  Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Asher Zilberstein,et al.  Induction of autocrine epidermal growth factor receptor ligands in human keratinocytes by insulin/insulin‐like growth factor‐1 , 1995, Journal of cellular physiology.

[10]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[11]  R. Nicholson,et al.  Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.

[12]  P. Brodt,et al.  Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. , 2000, Biochemical pharmacology.

[13]  N. Anderson,et al.  The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[14]  B. Calabretta,et al.  Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.

[15]  E. Surmacz.  Function of the IGF-I Receptor in Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[16]  M. Gishizky,et al.  SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling , 2000, Molecular and Cellular Biology.

[17]  A. Lykkesfeldt,et al.  Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha. , 2003, Endocrine-related cancer.

[18]  D. Yee,et al.  The IGF system and breast cancer. , 2001 .

[19]  S. Hilsenbeck,et al.  Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  R. Nicholson,et al.  Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.

[21]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[22]  C Collins,et al.  Insulin‐like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. , 1986, The EMBO journal.

[23]  A. Lykkesfeldt,et al.  Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. , 1993, European journal of cancer.

[24]  M. Maa,et al.  c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.

[25]  M. Lynch,et al.  Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. , 1992, British Journal of Cancer.

[26]  P. Glazer,et al.  Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. , 1997, Cancer research.

[27]  E. Surmacz,et al.  Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. , 1997, Cancer research.

[28]  W. Sly,et al.  Insulin-like growth factor receptor expression and function in human breast cancer. , 1990, Cancer research.

[29]  M. Boylan,et al.  Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. , 1996, Cancer letters.

[30]  N. Lydon,et al.  Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α (*) , 1995, The Journal of Biological Chemistry.

[31]  I. Ellis,et al.  Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy , 2004, Breast Cancer Research and Treatment.

[32]  J. Battey,et al.  Insulin-like Growth Factor Expression in Human Cancer Cell Lines (*) , 1996, The Journal of Biological Chemistry.

[33]  J. Siegfried,et al.  Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells , 2004, Cancer Research.

[34]  C. Ohlsson,et al.  Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells. , 1996, The Journal of endocrinology.

[35]  Adrian V. Lee,et al.  Crosstalk Between the Insulin-Like Growth Factors and Estrogens in Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[36]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[37]  P. Elizalde,et al.  Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells , 2001, Oncogene.

[38]  D. Yee,et al.  Insulin-like growth factors and breast cancer. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[39]  I. H. Hamelers,et al.  Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. , 2003, Endocrine-related cancer.

[40]  M. Brattain,et al.  Activation of the TGFα autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells , 2002, Oncogene.

[41]  J. Lippincott-Schwartz,et al.  Formation of stacked ER cisternae by low affinity protein interactions , 2003, The Journal of cell biology.

[42]  R. Nicholson,et al.  erbB Signalling and Endocrine Sensitivity of Human Breast Cancer , 1997 .

[43]  F. Kern,et al.  MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo , 1995, Breast Cancer Research and Treatment.

[44]  J. Coll,et al.  Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines* , 2002, The Journal of Biological Chemistry.

[45]  B. H. Shah,et al.  Roles of Src and Epidermal Growth Factor Receptor Transactivation in Transient and Sustained ERK1/2 Responses to Gonadotropin-releasing Hormone Receptor Activation* , 2003, Journal of Biological Chemistry.

[46]  K. L. Pierce,et al.  Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.

[47]  A. Levitzki,et al.  Specific Inhibition of Insulin-Like Growth Factor-1 and Insulin Receptor Tyrosine Kinase Activity and Biological Function by Tyrphostins. , 1997, Endocrinology.

[48]  R. Baserga,et al.  Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor. , 1996, Experimental cell research.